IN2014CN02458A - - Google Patents
Info
- Publication number
- IN2014CN02458A IN2014CN02458A IN2458CHN2014A IN2014CN02458A IN 2014CN02458 A IN2014CN02458 A IN 2014CN02458A IN 2458CHN2014 A IN2458CHN2014 A IN 2458CHN2014A IN 2014CN02458 A IN2014CN02458 A IN 2014CN02458A
- Authority
- IN
- India
- Prior art keywords
- inflammation
- ectoin
- apoptosis
- hydroxyectoin
- neutrophiles
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 abstract 3
- 230000004054 inflammatory process Effects 0.000 abstract 3
- 230000006907 apoptotic process Effects 0.000 abstract 2
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 abstract 2
- KIIBBJKLKFTNQO-WHFBIAKZSA-N 5-hydroxyectoine Chemical compound CC1=N[C@H](C(O)=O)[C@@H](O)CN1 KIIBBJKLKFTNQO-WHFBIAKZSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000003714 granulocyte Anatomy 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000003448 neutrophilic effect Effects 0.000 abstract 1
- -1 salt ester Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a composition comprising ectoin hydroxyectoin and/or a salt ester or amide of these compounds for suppression of anti apoptotic signals to neutrophilic granulocytes and other cells involved in inflammation. The retarded apoptosis of neutrophiles is a main component for various kinds of inflammation. Administration of ectoin achieves at least partial restoration of the normal apoptosis rate which is associated with a corresponding improvement in the inflammation symptoms.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011113059A DE102011113059A1 (en) | 2011-09-09 | 2011-09-09 | Therapeutic Applications of Ectoin |
| PCT/EP2012/003757 WO2013034299A1 (en) | 2011-09-09 | 2012-09-07 | Therapeutic uses of ectoin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02458A true IN2014CN02458A (en) | 2015-08-07 |
Family
ID=47115708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2458CHN2014 IN2014CN02458A (en) | 2011-09-09 | 2012-09-07 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140315869A1 (en) |
| EP (2) | EP3287131B1 (en) |
| JP (2) | JP6250542B2 (en) |
| CN (1) | CN103857394A (en) |
| BR (1) | BR112014005414A2 (en) |
| CA (1) | CA2848010A1 (en) |
| DE (1) | DE102011113059A1 (en) |
| ES (2) | ES2795879T3 (en) |
| IN (1) | IN2014CN02458A (en) |
| PL (2) | PL3287131T3 (en) |
| RU (1) | RU2648475C2 (en) |
| WO (1) | WO2013034299A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160106747A1 (en) * | 2008-01-30 | 2016-04-21 | Bitop Ag | Treating postoperative mechanical stress with an ectoine |
| DE102008039231A1 (en) | 2008-08-22 | 2010-02-25 | Bitop Ag | Use of glucosylglycerol |
| DE102014007423A1 (en) * | 2014-05-22 | 2015-11-26 | Bitop Ag | Composition for the treatment of the eye |
| DE102014113781A1 (en) * | 2014-09-23 | 2016-03-24 | Bitop Ag | Solut and solute mixture and a composition containing at least one solute for use in the prevention or treatment of induced by suspended particulate cosmetic or pathological Effloreszenzen |
| DE102015121050A1 (en) * | 2015-12-03 | 2017-06-08 | Bitop Ag | A compatible solute or solute mixture for use in the prevention or treatment of diseases with barrier defects in epithelial tissues |
| DE102016104470A1 (en) | 2016-03-11 | 2017-09-14 | Bitop Ag | Composition for promoting the activity of sirtuins |
| CN111936142A (en) * | 2018-04-05 | 2020-11-13 | 株式会社资生堂 | ASMT expression promoter |
| CN114425056A (en) * | 2020-10-14 | 2022-05-03 | 宁波希诺赛生物科技有限公司 | Stem cell exosome composition for improving asthma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4244580A1 (en) | 1992-12-31 | 1994-07-07 | Galinski Erwin A | Process for the in vivo extraction of ingredients from cells |
| DE4342560A1 (en) * | 1993-12-14 | 1995-06-22 | Marbert Gmbh | Use of 1,4,5,6-tetra:hydro-4-pyrimidine carboxylic acid derivs. in cosmetics |
| WO2000036915A1 (en) * | 1998-12-22 | 2000-06-29 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
| AU5812800A (en) * | 1999-06-12 | 2001-01-02 | Stefan Barth | Pharmaceutical preparation |
| DE10006578C2 (en) * | 2000-02-14 | 2002-10-31 | Bitop Ag | Use of compatible solutes as inhibitors of the enzymatic degradation of macromolecular biopolymers |
| DE10065986A1 (en) | 2000-12-21 | 2002-07-11 | Bitop Gmbh | Pharmaceutical formulation, especially a vaccine, e.g. against polio or parvovirus, contains proteins, peptides and/or nucleic acids as well as compatible solutes |
| DE10330243A1 (en) | 2003-07-03 | 2005-01-20 | bitop Aktiengesellschaft für biotechnische Optimierung | Use of osmolytes derived from extremophilic bacteria for the manufacture of medicines for the external treatment of atopic dermatitis |
| DE10330768A1 (en) | 2003-07-07 | 2005-02-24 | bitop Aktiengesellschaft für biotechnische Optimierung | Use of osmolytes obtained from extremophilic bacteria for the preparation of inhalable medicaments for the prophylaxis and treatment of pulmonary and cardiovascular diseases, and an inhalation device containing osmolyte as an active ingredient |
| DE102006056766A1 (en) | 2006-12-01 | 2008-06-05 | Bitop Ag | Use of compatible solutes |
| DE102007040615A1 (en) * | 2007-08-27 | 2009-03-05 | Bitop Ag | Osmolyte for the treatment of allergic or viral respiratory diseases |
-
2011
- 2011-09-09 DE DE102011113059A patent/DE102011113059A1/en active Pending
-
2012
- 2012-09-07 IN IN2458CHN2014 patent/IN2014CN02458A/en unknown
- 2012-09-07 RU RU2014113906A patent/RU2648475C2/en not_active IP Right Cessation
- 2012-09-07 CA CA2848010A patent/CA2848010A1/en not_active Abandoned
- 2012-09-07 CN CN201280049557.3A patent/CN103857394A/en active Pending
- 2012-09-07 US US14/343,017 patent/US20140315869A1/en not_active Abandoned
- 2012-09-07 PL PL17189829T patent/PL3287131T3/en unknown
- 2012-09-07 EP EP17189829.9A patent/EP3287131B1/en active Active
- 2012-09-07 JP JP2014528897A patent/JP6250542B2/en active Active
- 2012-09-07 BR BR112014005414A patent/BR112014005414A2/en not_active Application Discontinuation
- 2012-09-07 WO PCT/EP2012/003757 patent/WO2013034299A1/en active Application Filing
- 2012-09-07 ES ES17189829T patent/ES2795879T3/en active Active
- 2012-09-07 ES ES12780649.5T patent/ES2657907T3/en active Active
- 2012-09-07 EP EP12780649.5A patent/EP2753330B1/en active Active
- 2012-09-07 PL PL12780649T patent/PL2753330T3/en unknown
-
2017
- 2017-07-07 JP JP2017133770A patent/JP6396544B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6396544B2 (en) | 2018-09-26 |
| BR112014005414A2 (en) | 2017-04-04 |
| EP2753330A1 (en) | 2014-07-16 |
| PL3287131T3 (en) | 2020-10-19 |
| EP2753330B1 (en) | 2017-11-08 |
| ES2657907T3 (en) | 2018-03-07 |
| JP6250542B2 (en) | 2017-12-20 |
| EP3287131A1 (en) | 2018-02-28 |
| CA2848010A1 (en) | 2013-03-14 |
| US20140315869A1 (en) | 2014-10-23 |
| JP2017197569A (en) | 2017-11-02 |
| ES2795879T3 (en) | 2020-11-25 |
| RU2648475C2 (en) | 2018-03-26 |
| PL2753330T3 (en) | 2018-05-30 |
| CN103857394A (en) | 2014-06-11 |
| WO2013034299A1 (en) | 2013-03-14 |
| JP2014526448A (en) | 2014-10-06 |
| DE102011113059A1 (en) | 2013-03-14 |
| RU2014113906A (en) | 2015-10-20 |
| EP3287131B1 (en) | 2020-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN02458A (en) | ||
| ZA201703041B (en) | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy due to energy failure | |
| HK1220409A1 (en) | Novel compounds and compositions for inhibition of fasn fasn | |
| EA201391033A1 (en) | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| EP3725811A3 (en) | Compositions for inhibiting masp-2 dependent complement activation | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| IN2013CN02463A (en) | ||
| MY192285A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| PL2780036T3 (en) | Nanoparticle compositions for generation of regulatory t cells and treatment of autoimmune diseases and other chronic inflammatory conditions | |
| MX359146B (en) | Compound as wnt signaling inhibitor, composition, and use thereof. | |
| EP2929886A4 (en) | Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells | |
| IN2014DN05772A (en) | ||
| IN2014MN02121A (en) | ||
| MX2014002988A (en) | Process and composition for inhibiting the polymerization of cyclopentadiene compounds. | |
| GB201101331D0 (en) | Compositions and uses | |
| MX337612B (en) | Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome. | |
| HK1180951A1 (en) | Agent for suppressing the formation of abnormal skin cells caused by exposure to light | |
| HRP20190182T1 (en) | Methods for alleviating symptoms of multiple sclerosis based on apoaequorin-containing compositions | |
| WO2011105902A3 (en) | Antagonists of complement component 8-beta (c8-beta) and uses thereof | |
| WO2011105900A3 (en) | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof | |
| WO2011105901A3 (en) | Antagonists of complement component 9 (c9) and uses thereof | |
| EP3063312A4 (en) | The use of niobate containing compounds as corrosion inhibitors | |
| HRP20160663T1 (en) | Formulation of compositions for the treatment of inflammatory conditions | |
| PT2709606T (en) | Compositions containing resveratrol and essential oil of cloves for the treatment of itching |